



2020

Strategic clinical study partnering service for K & S-Bio startups

C&R HEALTHCARE GLOBAL

August 2020

Helen Kim, Ph.D.

C&R Healthcare Global established in 2017 as an Asian business hub in Singapore to support Korean bio-healthcare companies seeking global market entry. To meet requests for a comprehensive growth strategy beyond R&D, we assist in everything from advice to business incubation in Singapore and access an advanced ecosystem network of investors, consultants, and consumers.



C&R Healthcare Global office



MoU with Golden Equator Group



SPECTRUM

C&R Healthcare Global has been providing the optimal growth program for 15 biomedical & healthcare start-ups and SMEs.



Dotter

Bioabsorbable Stent with Phosphorylcholine Groups



Bioinfra Life Science

Multi-biomarker Blood Test for Analyzing 8 Major Cancers



TI Inc.

Development of Surgical Instruments Using Wire Rope and High Frequency



Humanscape

Humanscape

A Blockchain-based Patient Network



LABnPEOPLE

Bioabsorbable metal and Minimal invasive medical device



CellSafe

Mycoplasma Total Solution



Olix

Development of Therapeutics Based on Oligonucleotide Platform



Stemore

Development of Total Hair Solution for Hair Loss Prevention



sureAssist

GMP Consulting



Edenlux

Personal vision training device made by an eye health specialist



GC Cell

Development of Cancer Immunotherapy



Sungwon Medical

Manufacture of Medical Devices



iMediSync

EEG Analysis Solution based on National Reference Standard Database



AllLive Healthcare

Digital clinical trials platform



Bareun

Seven natural ingredients for oral healthcare

About C&R Research

C&R Research is the first CRO in South Korea established in 1997. As a full-service CRO, C&R Research provides comprehensive scope of services from clinical trials to regulatory and consulting. C&R Research has established a global network with an exceptional strength in the Asian regions and served as a gateway into Asia for global partners. Also, as a total value chain CRO, it offers services that reach beyond those of conventional CROs. From drug discovery to commercialization, C&R Research increases capability through constant collaboration with renowned Korean bio-health institutes.



Company Name	C&R Research
Foundation Year	1997
Headquarter	Seoul, South Korea
CEO	Mr. Yoon Tae Moon
Offices	Global: Singapore, Beijing Korea: Gangnam (Seoul), Busan
Workforce	300+


RESEARCH

A large, stylized graphic element consisting of a thick green outline of the letter 'R'. Inside the upper curve of the 'R', the word 'RESEARCH' is written in a bold, orange, sans-serif font.


Therapeutic Area

C&R Research has developed expertise in various therapeutic areas of clinical trials through wide range of experience. With a specialty in oncology studies, C&R's width of therapeutic expertise has set a solid foundation for C&R Research's clinical excellence.

Experiences by Therapeutic Area 2010-2019, Total: 1,020 studies



Experiences by Oncology Indications 2010-2019, Total: 144 studies



Strong Presence in Korea, Embedded Global Competitiveness

C&R Research has a strong network with Korea's major hospitals, ensuring access to a large pool of clinical trial patients and efficient site selection. The major hospitals have been conducting an increasing number of clinical trials with their significant advantages, and nearly half of them are multinational studies.

of Multinational Trials 2014-2018

Korea's Major Hospitals by Size (Top 15)

	Name	No. of Beds
	1 Seoul Asan Hospital	2,704
100 trials	2 Yonsei Severance Hospital	2,471
	3 Samsung Medical Center	1,869
120 trials	4 Seoul National University Hospital	1,786
70 trials	5 Seoul St. Mary Hospital	1,356
	6 Gacheon Univ. Gil Medical Center	1,400
	7 Chungnam National University Hospital	1,353
	8 Pusan National University Hospital	1,310
	9 Seoul National University Hospital, Bundang	1,309
	10 Aju University Hospital	1,179
	11 Pusan National University Hospital, Yangsan	1,173
	12 Chonbuk National University Hospital	1,104
	13 Korea University Hospital, Guro	1,074
	14 Korea University Hospital, Anam	1,051
	15 Chonnam National University Hospital	1,028
	20 Inha University Hospital	925
	31 Gangnam Severance Hospital	814

C&R Research's Partnerships with Korea's Major Hospitals



*Approximately 35% of Korea's clinical trials take place at the top 5 hospitals in Korea, also known as the "Big 5"

C&R Research's Partnerships with Renowned BioHealth Institutes



*highlights are C&R Research's partner hospitals Source: KoNECT

Our Leadership, Strong Presence In Global, Top CROs in APAC 2020

C&R Research was selected as the Top CRO of APAC in 2020 by pharma tech outlook



C&R Research Taking Korea's Pharma Companies International

pharma Top 10
CROs
IN APAC - 2020

In the age of the fourth Industrial Revolution, Korea's pharmaceutical and medical device industries are facing a more intensified global competitive landscape. To become a forerunner to lead the new industrial paradigm, seeking business diversification and globalization on the part of Korean companies will be an integral part for success. Korean pharmaceutical companies and bio companies often lack R&D or marketing capability as they do not have in-house global study teams, which leads them to hire foreign CROs for global market entry and to establish a business strategy. This led Moon-tae Yoon, an expert in the pharma industry, to found C&R Research, a full-service CRO that provides a comprehensive scope of clinical services for Korean pharmaceuticals and medical device companies. "Our primary goal is to support small to mid-sized Korean pharmaceutical companies that have limited means to conduct international clinical trials on their own," says Yoon, CEO of C&R Research.

C&R Research, established in 1997, is the first full-service CRO in Korea and has grown to become Korea's leading CRO. The company offers full-service coverage, including arranging contracts, drug development consulting, regulatory affairs, medical writing, clinical operation, project management, data management, statistical analysis, CSR writing, medical consulting, quality assurance, publication, education, and training. With its expertise, diverse network, and experienced staff, C&R Research ensures the delivery of efficiency and excellence in clinical services to optimize the client experience. For 24 years, with expertise in clinical development of pharmaceutical and medical device products, it has completed more than 1,500 projects and licensing procedures across most treatment areas.



A testimony to C&R Research's pharma abilities is a Korean bio company that needed to expedite the New Drug Application (NDA) for its fine-wrinkles product to be the first-in-market for the preparation of botulinum toxin. Due to the difficulties in coordinating staff and time management, the client sought support from C&R Research for efficient project management expertise in clinical operation. C&R Research helped the client make effective decisions through prompt issue sharing and communication strategies for sponsors and drastically reduced the timeline for the stages I/P0 to CSR, from the initial 19 weeks to 11 weeks. This helped the client's product to receive the fourth approval in the market. C&R overcame the challenges and established its expertise by streamlining each departments' project preparation, project manager appointment, and task management processes.

With a well-established market in Korea, C&R Research's goal is to become a total value chain CRO that provides end-to-end services, including technology investment and incubation, training programs, joint development services, and production distribution. Over the years, C&R Research also established integrated services through its subsidiaries and partners in Korea, China, and APAC

regions. It now aims to become a global CRO that covers major regions, including the U.S. and Europe. Currently, C&R Research is planning an M&A with a U.S. CRO to provide essential management and operation support to initiate early-stage clinical development for sponsors who may have a lack of experience in the U.S. and foreign market.


Our primary goal is to support small to mid-sized Korean pharmaceutical companies that have limited means to conduct international clinical trials on their own.

C&R Research is also operating an incubation business in Singapore, aiming to support Korea healthcare startups' entry into foreign markets. C&R Research has also developed a Central Lab to collect specimen from clinical trials in multiple sites to one laboratory for accurate clinical trial results based on GCLP (Good Clinical Laboratory Practice) in collaboration with a Korean company. In fact, some of C&R's global projects in China, the U.S., Bulgaria, and Australia are working in collaboration with local partners. C&R Research established an entity in China to enable numerous Korean pharmaceutical companies to enter the Chinese market as clients. What's more, C&R Research established CDISC systemization and central monitoring service to secure reliable and high-quality clinical data compliance with global standards. By operating the project and central monitoring simultaneously, C&R Research can identify risks in the early stage and reduce unnecessary time and cost, which results in positive feedback from the clients. 



Mr. ByungIn Yoon
CEO

GCCL, Inc.
Head Of BD
C&R Research, Inc.
CSO
C&R Research China, Ltd.
GM
➤ The support network of Korean pharmaceutical industry



Mr. Soowoong (Phillip) Kim
Executive Director

Strategic Planning Team
C&R RESEARCH Inc.
➤ The support network of government agencies such as Osong K-bio and KHIDI
➤ Europe and CIS network support



Helen Kim, Ph.D.
General Manager

➤ Strategic Business Development for healthcare Startup engagement and Open innovation



Ms. Semi Park (PM)
Ms. Nanyoung Yun

Strategic Planning Team
C&R RESEARCH Inc.
➤ National Project Proposal Management
➤ Market Research



Wang Ling
Assistant Manager

➤ Marketing and Global B2B development for K-Beauty

Our team works closely with the Korean headquarters and the Singapore branch with a global network of health professionals and experienced research and development of new medicines and an elite member who understands the business culture of Korea and Singapore.

In order to attract global investment, it is essential to enter the market as well as the excellent technology of the company, and to build a thoroughly prepared local business model. We look for business partners who may be most interested in our products and services in the oversea markets, research ways to work with them, and conduct meetings to arrange meetings with them.



Bayer Singapore



Roche Diagnostics Singapore



Allianz Insurance Singapore

What we've done in COVID-19 Pandemic

- C&R HG's business activities never stop amid the global Covid-19 crisis.
- Proposal of a collaborative project with the Korean medical community that wants to network with innovative companies in Singapore
- Reinforcement of online network with global innovation pharmaceutical companies and domestic innovation startups C-Level, researchers, and K-Bio news delivery
- Global clinical project review and investment project review using a pool of C&R Research clinical experts



[Figure 1] Global largest professional networking community Linked pharmaceutical HG network with over 800 people



[Figure 2] Project meeting with Singapore remote rehabilitation monitoring startup

No.	Company	Industry
1	Greencrosscell	biopharmaceutical
2	Neuracle SCIENCE	biopharmaceutical
3	DR,NOAH BIOTECH	biopharmaceutical
4	Daewoong Pharmaceutical CO., LTD.	biopharmaceutical
5	RaND Bioscience Inc.,	biopharmaceutical
6	Baobab AiBIO Co., Ltd.	biopharmaceutical
7	B2SBIO	biopharmaceutical
8	Samik Pharmaceutical Company LTD.	biopharmaceutical
9	CellinCells.isd	biopharmaceutical
10	AULBIO, Ltd.	biopharmaceutical
11	AHNGOOK PHARM	biopharmaceutical
12	Abclon Inc.	biopharmaceutical
13	APITBIO Co., Ltd	biopharmaceutical
14	Xcell Therapeutics Inc.,	biopharmaceutical
15	YD Life science Company	biopharmaceutical
16	Wooridul Pharmaceutical Ltd.	biopharmaceutical
17	Ignite Innovators.	biopharmaceutical
18	Inventagelab	biopharmaceutical
19	Chong Kun Dang pharmaceutical Corp,	biopharmaceutical
20	Genome & Company.	biopharmaceutical
21	G+FLAS®	biopharmaceutical
22	T&R Biofab	biopharmaceutical
23	Pharos I&BT Co., Ltd.	biopharmaceutical
24	DAEKYO Investment	Investment
25	SV INVESTMENT CO.,LTD.	Investment
26	I BInvestment	Investment
27	LSK investment Inc.	Investment

C&R Rooftop private networking party for LG Alumni (2019, Sep)



- LG Lifescience is a closed healthcare network which produce the first generation of K-Bio startups from 1990.
- C&R Research is one of the core member of the society.
- Media article: Life Science Alumni Association, experts in all fields of new drug development here
- <https://www.hellodd.com/?md=news&mt=view&pid=68979>

C&R Healthcare Global 2020

Medical Device (including Digital Healthcare), Pharmaceuticals and K-cosmetics

Business Development Service	Business Strategy	Open Innovation Search	Joint clinical study group Search	Distributor Search	
Regulatory Service	Regulatory Strategy	Clinical Trials	Quality Compliance	Product Registration	Reimbursement